Related Experiment Video
Updated: Feb 9, 2026

Quantification of Immunostained Caspase-9 in Retinal Tissue
Published on: July 25, 2022
Dasatinib reduces 5-Fu-triggered apoptosis in colon carcinoma by directly modulating Src-dependent caspase-9
Yang Fu1, Ge Yang2, Peipei Xue3,4
11Department of General Surgery, The First Affiliated Hospital of Zhengzhou University, 450052 Zhengzhou, China.
Abstract:
Preclinical data have revealed the inhibitory effect of dasatinib on colon cancer. However, a combination of dasatinib and conventional chemotherapy has failed to show any meaningful outcome in a series of clinical trials. We, therefore, wondered whether Src kinase inhibitors were suitable for treating colon cancer in combination with chemotherapy drugs. This study was designed to explore whether dasatinib disturbed 5-Fu-triggered apoptosis in colon carcinoma. As a result, we established that Src was able to directly phosphorylate caspase-9 at tyrosine 251, leading to elevated caspase-9 activity. Dasatinib dramatically decreased 5-Fu triggered apoptosis in colon carcinoma via suppression of Src activation. Our findings may have partially explained why dasatinib combined with FOLFOX failed to show a meaningful clinical response in mCRC.
Insights
Dasatinib inhibits colon cancer cell death induced by 5-fluorouracil (5-FU) by blocking Src kinase activation, which is crucial for caspase-9 activity. This finding may explain why dasatinib and FOLFOX chemotherapy failed in metastatic colorectal cancer (mCRC) clinical trials.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Preclinical studies suggested dasatinib inhibits colon cancer.
- Clinical trials combining dasatinib with chemotherapy (FOLFOX) showed limited efficacy in metastatic colorectal cancer (mCRC).
- The role of Src kinase inhibitors in combination cancer therapy remains unclear.
Purpose of the Study:
- To investigate if dasatinib interferes with 5-fluorouracil (5-FU)-induced apoptosis in colon carcinoma.
- To explore the mechanism by which dasatinib affects chemotherapy response in colon cancer.
Main Methods:
- Western blotting to detect protein phosphorylation.
- Assays to measure caspase-9 activity.
- Cellular apoptosis assays in colon carcinoma models.
Main Results:
- Src kinase directly phosphorylates caspase-9 at tyrosine 251, enhancing its activity.
- Dasatinib treatment suppressed Src activation.
- Dasatinib significantly reduced 5-FU-triggered apoptosis in colon carcinoma cells by inhibiting Src activation.
Conclusions:
- Dasatinib interferes with 5-FU-induced apoptosis in colon cancer by suppressing Src kinase.
- Src kinase activation is essential for 5-FU-induced apoptosis via caspase-9.
- The findings provide a potential explanation for the clinical failure of dasatinib-FOLFOX combination therapy in mCRC.
Related Concept Videos
Phosphorylation
During phosphorylation, protein kinases transfer the terminal phosphate group of ATP to specific amino acid side chains of substrate proteins. Serine, threonine, and tyrosine are the most commonly...
Caspases
Apoptosis
The Colonization of Land
5-Number Summary
In a box plot, the minimum and maximum data values represent the lower and upper whiskers in the graph, and the median is designated as the center of the box in the chart. The first quartile and third...
Conservation of Protein Domains Over Different Proteins
A limited set of protein domains often duplicate and recombine during evolution. These domains can be organized in different combinations to...

